Back to top
more

Argenx (ARGX)

(Delayed Data from NSDQ)

$365.81 USD

365.81
110,206

-10.79 (-2.87%)

Updated May 17, 2024 04:00 PM ET

After-Market: $366.18 +0.37 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ARGX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

6 items in cart

View Cart/Checkout

argenex SE [ARGX]

Reports for Purchase

Showing records 141 - 160 ( 278 total )

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 141

07/21/2021

Company Report

Pages: 16

2021 R&D Day Highlights; The Journey Adds New Indications

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 142

07/19/2021

Industry Report

Pages: 18

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 143

07/15/2021

Daily Note

Pages: 4

argenx to Unveil 5th & 6th Efgartigimod Indications and Phase 1 Data for -117 at Virtual R&D Day; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 144

07/12/2021

Industry Report

Pages: 17

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 145

07/07/2021

Industry Report

Pages: 17

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 146

06/28/2021

Industry Report

Pages: 18

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 147

06/11/2021

Industry Report

Pages: 9

Takeaways From ASCO 2021 Across Our Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 148

06/08/2021

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 149

06/08/2021

Daily Note

Pages: 3

J&J Returns Cusatuzumab Though argenx’s Focus Remains on Efgartigimod and Immunology Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 150

06/07/2021

Company Report

Pages: 5

Parting Is Sweeter After $500+M; Janssen Returns Cusa

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 151

05/17/2021

Company Report

Pages: 5

Building-Out the Global Efgartigimod Franchise With J-MMA Filing Acceptance; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 152

05/17/2021

Company Report

Pages: 6

Efgartigimod: Buy in May and Walk Away

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 153

05/10/2021

Industry Report

Pages: 11

Safety Rules: We Upgrade argenx as Survey Points to Market Leadership for Efgartigimod

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 154

05/10/2021

Company Report

Pages: 7

We See Efgartigimod Emerging as the Leader in the FcRn Market; Upgrade to Buy, PT to $400

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 155

04/26/2021

Industry Report

Pages: 8

Key Takeaways From Our Coverage at the American Academy of Neurology 2021 Virtual Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 156

04/22/2021

Daily Note

Pages: 3

Additional Nipocalimab Data Doesn’t Offer Clarity on Albumin Levels or Potential Cholesterol Changes

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 157

03/05/2021

Company Report

Pages: 5

With MG BLA Submitted, Focus Shifts to Launch Preparations; Reiterate Neutral Price Target up to $320

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 158

03/04/2021

Company Report

Pages: 8

Not Too Early to Think of Christmas; Efgart PDUFA Set in Dec.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 159

03/01/2021

Industry Report

Pages: 16

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: argenex SE

Industry: Medical - Biomedical and Genetics

Record: 160

02/01/2021

Company Report

Pages: 7

Sticking to CIDP with Efgart in ADHERE Study

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party